Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saxagliptin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saxagliptin Anhydrous SCHEMBL882684 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL15579932 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL2742680 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL15752149 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL12518855 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL23752173 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL8250350 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17131050 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL8277138 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17168 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| US-9616028-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2017-04-11 | — | — | US | disclosed |
| US-9616028-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2017-04-11 | — | — | US | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| WO-2016046679-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | disclosed |
| US-20150238421-A1 | Bilayer Tablet Formulations | ASTRAZENECA AB (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20150238421-A1 | Bilayer Tablet Formulations | ASTRAZENECA AB (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140255486-A1 | Coated Tablet Formulation and Method | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | disclosed |
| EP-2611770-A1 | PROCESS FOR THE REDUCTIVE AMINATION OF -KETO CARBOXYLIC ACIDS | Sandoz AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028721-A1 | PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS | SANDOZ AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20110200672-A1 | COATED TABLET FORMULATION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-7951400-B2 | Coated tablet formulation and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| WO-2008098256-A1 | METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF RESPONDING TO DPP-IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238421-A1 | Bilayer Tablet Formulations | SLC5A2, SLC5A1, GLP1R | DPP4 16/4885CYP3A4 990/4885DPP8 21/4885 |
| US-20140255486-A1 | Coated Tablet Formulation and Method | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 125/4885DPP8 5/4885 |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | DPP4 1/4885CYP3A4 25/4885DPP8 19/4885 |
| US-20110200672-A1 | COATED TABLET FORMULATION AND METHOD | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 69/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.